Scandion Oncology will significantly enhance the patent protection of its lead compound SCO-101 in the important US market. Scandion has received a Notice of Allowance from the United States Patent and Trademark Office meaning a patent will officially be granted following payment of the issue fee, which will be done shortly. The patent will cover methods of using SCO-101 and any other so-called VRAC modulator to sensitize cancer cells to any anti-cancer agent or potentiate the therapeutic effect of any anti-cancer agent.

The patented methods will cover treatment of a comprehensive range of specific cancers, including colorectal and pancreatic cancer, regardless of whether the cancers are resistant to current treatments or not. Thus, the patent offers a very broad intellectual protection until at least 2037, which will allow Scandion to potentially target also earlier lines of treatment. When granted, the patent will enhance Scandion's existing patent exclusivity on SCO-101 in the US, which currently includes a patent on combination therapy of resistant cancers.

The patent protection of SCO-101 was already recently significantly strengthened by the granting of a new Composition-of-Matter patent by the European Patent Office in November 2023. SCO-101 is currently being clinically developed as a combination treatment for metastatic colorectal cancer and pancreatic cancer. Scandion believes that SCO-101 can revert cancer's resistance to treatments like chemotherapy thereby making the treatments work better and longer.

cancer drug resistance continues to constitute a huge unmet medical need.